semaglutide and cardiovascular outcomes in patients with type 2 diabetes Series: outcome trials for drugs SUSTAIN-6 Oral Semaglutide and Cardiovascular Outcomes

It cannot currently be prescribed for weight loss, and any retatrutide vs tirzepatide comparison remains theoretical until that review is complete

By curbing oxidative stress and inflammatory responses, GLP-1 RAs can help protect kidney cells from damage, making these drugs particularly useful for diabetic patients with AKD

Both are approved by the Food and Drug Administration (FDA) and are available as oral tablets to be taken once daily

If your medication freezes, it must be discarded and replaceddo not use frozen or previously frozen GLP-1 injections

GLP-1 injection pens represent a significant financial consideration, with estimated list prices typically ranging from $800 to $1,400 per month without insurance coverage

These findings support the potential of these compounds as adjunctive therapeutic strategies